Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

KX-826 shows promising results for hair growth with fewer side effects, offering an alternative to finasteride and minoxidil. Users discuss combining it with minoxidil, dermarolling, and Nizoral for improved results.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Topical dutasteride 0.05% is more effective for hair growth than oral finasteride 1mg, with minimal DHT reduction. The formulation uses castor oil and MCTs for better absorption but is not widely available until 2028.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

GT20029 shows promising results for hair loss treatment, with potential approval in China by 2026 or 2027, but U.S. approval may take longer. It could serve as an alternative to finasteride, with a potentially better side effect profile.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

A user plans to switch from finasteride to dutasteride for better hair loss treatment, citing dutasteride's higher DHT suppression. Others share mixed experiences, discussing transition methods, shedding, and potential side effects.

KX-826 is undergoing Phase III trials in China as a potential treatment for male pattern baldness, with some users considering it as an alternative or addition to finasteride and dutasteride. Opinions on its effectiveness vary, with some users reporting positive results and others finding it expensive and ineffective.

A 26-year-old male shared results after using Minoxidil twice daily and dermarolling weekly for two months, seeking advice on additional treatments for better hair growth. Another user discussed their experience with finasteride and considered trying dutasteride due to concerns about hair shedding and lack of regrowth.

The conversation discusses the challenges and experiences of using minoxidil, finasteride, and dutasteride for hair loss, focusing on the shedding phase and its impact on hair appearance. Users share their personal experiences, side effects, and hopes for improvement, with some considering or having undergone hair transplants.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

The conversation discusses the failure of Phase 3 trials for the hair loss treatment KX-826, with no significant difference found between the drug and placebo. Some users express disappointment and skepticism, while others discuss alternative treatments like Minoxidil, finasteride, and RU58841.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

Breezula shows promising hair growth results, with up to 539% increase in hair count compared to placebo, and regulatory submissions are planned in the US and EU. Users are cautiously optimistic, noting the potential for Breezula to replace finasteride by targeting DHT without systemic effects.

A 22-year-old stabilized hair loss with oral finasteride and minoxidil but sees minimal regrowth. They received conflicting transplant advice, with graft recommendations from 1,600 to 4,000, and concerns about diffuse thinning and donor area.

Many users report not experiencing a shedding phase while using finasteride, with some also using minoxidil or dutasteride without shedding. Some believe shedding might be mistaken for normal hair loss, while others note micro sheds or no shedding at all.

A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.

The user stopped using minoxidil due to scalp issues and switched to finasteride, noticing thicker hair initially but experiencing hair loss again. They are considering restarting minoxidil but are concerned about the shedding phase, especially with upcoming vacation plans and a potential second hair transplant.

PP405 shows some hair growth after 4 weeks, but results are debated and expectations should be tempered. Some users compare it to minoxidil or finasteride, questioning its effectiveness and commercialization timeline.

The user has been using 3mg oral minoxidil, 1mg finasteride, microneedling, and topical 5% minoxidil for hair loss. They are unsure about the results, noticing some regrowth but feeling dissatisfied overall.

Creatine is believed by some to cause hair loss, potentially by increasing DHT levels, despite conflicting evidence. Users report mixed results when combining creatine with treatments like finasteride, dutasteride, and minoxidil.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.

The user is considering stopping finasteride due to depression, anxiety, and difficulty building muscle, despite its effectiveness in stopping hair loss. Suggestions include reducing the dose, switching to topical solutions, or consulting a doctor for alternatives like dutasteride or RU58841.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.